Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open Label, Multi-Center Study For The Evaluation Of The Combination Of CpG 7909 And Herceptin® In Patients With Metastatic Breast Cancer

NCT00031278 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00031278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00031278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open Label, Multi-Center Study For The Evaluation Of The Combination Of CpG 7909 And Herceptin® In Patients With Metastatic Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2001
Completion date
June 30, 2003
Enrollment
12 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, metastatic breast